BiomX Inc. (NYSEAM: PHGE)
Health Care · Biotechnology · US
$0.13
-4.73% today · -98.7% 1Y
BiomX Inc. (NYSEAM: PHGE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.40M and employs 20 people.
Over the last twelve months the share price has lost 98.7%, trading between 0.12 and 12.29.
Tweenvest scores BiomX Inc. across four factors: quality 21/100. Its strongest factor is quality.
PHGE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.40M
- Revenue (TTM)
- $332.00K
- P/E
- —
- EPS
- -10.93
- Dividend yield
- —
- Beta (5Y)
- 1.37
- 52-week high
- $12.29
- 52-week low
- $0.12
- Avg volume (3M)
- —
- Shares outstanding
- 10.15M
- Employees
- 20
- Next earnings
- —
About BiomX Inc.
Operating as a holding company, BiomX Inc. is dedicated to advancing technologies within the realms of defense, security, and essential infrastructure. Its diverse array of offerings features specialized solutions like counter-unmanned aerial vehicle systems, intelligent AI-powered command-and-control, comprehensive border and perimeter protection, expansive surveillance capabilities, and aerial fire suppression tools. The firm caters to a broad spectrum of clients, encompassing national defense organizations, primary government contractors, transportation management entities, local municipalities, and key infrastructure operators. BiomX Inc. commenced operations in 2015 and maintains its principal office in Dover, Delaware.
- ISIN
- US09090D5095
- Founded
- 2015
- Listed since
- Mar 13, 2019
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.